Market News AIOpen the app

JBIO stock news · Jade Biosciences, Inc.

Stories about Jade Biosciences, Inc. (JBIO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for JBIO

Follow Jade Biosciences, Inc. (JBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JBIO
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 7:22 AM ET · Market

    Jade Biosciences shared its financial results for the third quarter of 2026 and updates on its drug trials.

    Good for JBIO

    Jade reported $475.7 million in cash and expects it to fund operations into Q4 2028 as its trials advance. This strengthens the company's outlook despite higher research spending.

  2. Sep 30, 2026, 7:19 AM ET · Market

    Jade Biosciences, Inc. shares news about its drug JADE301 for treating dermatomyositis.

    Good for JBIO

    Jade reported promising JADE301 lab and animal results, including strong target blocking and no observed safety problems. The findings support its drug outlook, though human testing has not begun.